Evidence map›Paper›PMID 35638853›Full record

ArticleMicrobiology spectrum2022

Impact of the SARS-CoV-2 Pandemic on the Prevalence and Incidence of Gastrointestinal Viruses in Children up to Five Years Old: a Retrospective Cohort Study.

Alfredo Maldonado-Barrueco, Julio García-Rodríguez, Jorge Yániz-Ramirez, Irene Serrano-Vaquero, Juan Carlos Parra-Alonso, Carlos Vega-Nieto, Guillermo Ruiz-Carrascoso

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Characteristics of Gastroenteritis Outbreaks Investigated in Singapore: 2018-2021.International journal of environmental research and public health · 2024
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Alfredo Maldonado-BarruecoClinical Microbiology and Parasitology Department, Hospital Universitario La Pazgrid.81821.32, Madrid, Spain.ORCID 0000-0002-1856-1725
Julio García-RodríguezClinical Microbiology and Parasitology Department, Hospital Universitario La Pazgrid.81821.32, Madrid, Spain.
Jorge Yániz-RamirezFaculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.
Irene Serrano-VaqueroFaculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.
Juan Carlos Parra-AlonsoFaculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.
Carlos Vega-NietoFaculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.
Guillermo Ruiz-CarrascosoClinical Microbiology and Parasitology Department, Hospital Universitario La Pazgrid.81821.32, Madrid, Spain.ORCID 0000-0002-8957-6596
Universidad Autónoma de Madrid · ESHospital Universitario La Paz · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim is determining the impact of non-pharmaceutical measures (NPIs) against SARS-CoV-2 in the incidence and prevalence of gastrointestinal viruses (GV) in children. Demographic, analytical, and clinical data of children from which samples were received at the Hospital Universitario La Paz (Madrid, Spain) and that had a gastrointestinal infection with a positive sample through multiplex-PCR for GV were collected. The time periods included were prepandemic (P1): March 14, 2019 to March 14, 2020 and pandemic (P2): March 15, 2020 to March 15, 2021. The global prevalence, relative incidence (RI, per 1,000 admissions) and absolute incidence (AI, per 100,000 population) of GV were compared for both time periods. The prevalence of GV versus SARS-CoV-2 was determined for P2. Seven-hundred and 50 out of 2,547 children analyzed in P1 and 106 out of 1,368 in P2 were positive by PCR for GV (46.3% decrease in P2). Prevalence and RI of GV declined in P2, except for the RI of rotavirus. Adenovirus showed the largest decreased of prevalence and RI (100%), followed by sapovirus. Astrovirus reduction was less pronounced (3.1% versus 0.4%). Norovirus was the most frequent virus in both time periods and its prevalence and RI also decreased in P2 (15.2% versus 4.7% and 3.40 versus 1.74, respectively). Rotavirus had the smallest decrease in prevalence (2.6% versus 2.5%), and its RI increased during P2 from 0.7 to 0.93. After removing the rotavirus vaccine strains from the analysis, the prevalence and RI decreased during P2 (2.1% to 0.7% and 0.5 to 0.3, respectively). The AI decreased during P2 in all GV, and the prevalence of SARS-CoV-2 and GV was inversely proportional over time. Prevalence and incidence of GV have decreased during the pandemic, probably due to the implementation of NPIs against this virus and the reduction of health care attention to infections other than COVID-19. The differences in the decrease of prevalence and incidence for each virus may be explained by differences in the transmission and the resistance in the environment. Prevalence and RI of rotavirus might be biased since the PCR used detects both the infecting and the vaccine strains.

Indexed as

Communicable DiseasesCOVID-19GastroenteritisGastrointestinal DiseasesRotavirusVirusesChildFecesHumansIncidenceInfantPandemicsPrevalenceRetrospective StudiesSARS-CoV-2adenovirusesastroviruschildrengastrointestinal virusesnorovirusesoral vaccinesrotavirussapovirusSARS-CoV-2

Identifiers

PMID35638853
PMCPMC9241842
OpenAlexW4281674135

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.